NeuroMetrix (NSDQ:NURO) said last week that it raised $14.7 million in its most recent funding round. Waltham, Mass.-based NeuroMetrix said it sold 147,000 shares at $100 per share and repurchased all of the outstanding shares of its Series A-4 convertible preferred stock for approximately $3.2 million. The proceeds are slated to be used to fund the commercial […]
Neuromodulation/Neurostimulation
Sorin shareholders OK Cyberonics merger
Sorin Group (BIT:SRN) said shareholders met today and approved its upcoming merger with Cyberonics (NSDQ:CYBX). The deal, which is slated to bring together global leaders in neuromodulation and cardiac surgery with a combined equity value of $2.7 billion, is expected to close by the end of the 3rd quarter. Sorin stockowners will receive 0.0472 units of […]
Mind-controlled prosthetic limbs allow precise, smooth movement
Weight loss: 1st commercial implant of EnteroMedics’ Maestro device
St. Jude launches Prodigy spinal cord stimulator in Canada
Neuronetics raises $34m for anti-depression device
Neuronetics said it raised $34.3 million in an equity offering slated to help broaden the use of its anti-depression device that relies on magnetic stimulation of the brain.
Autonomic Technologies raises $38m in Series D round
Boston Scientific challenges Nevro patent
ImThera begins pivotal trial for Aura6000 sleep apnea implant
ImThera Medical said the 1st 2 U.S. patients in a clinical study of its Aura6000 sleep apnea therapy were successfully implanted with the device. The surgeries were performed by Dr. Sam Mickelson of Advanced Sleep Centers in Atlanta, Ga.
FDA OKs trial for StimGuard’s bladder implant
StimGuard said it won an investigational device exemption from the FDA for a clinical trial of its micro-size implantable device to treat overactive bladder syndrome. StimGuard said its system uses a small injectable microchip and an external transmitter and requires no invasive surgery to implant. The trial is slated to begin in summer 2015.